CC
ITCI

CIBRA Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

CIBRA Capital’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$54.9M Buy
+416,218
New +$51.9M 18.76% 1

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

CIBRA Capital's ITCI Position: Q1 2025 in Review

CIBRA Capital opened a new position in Intra-Cellular Therapies Inc. (ITCI) in Q1 2025: 416,218 shares worth $54.9M. The stake represents 18.76% of the portfolio and ranks #1 among its holdings.

395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • CIBRA Capital held 416,218 shares of Intra-Cellular Therapies Inc. worth $54.9M as of Q1 2025.
  • Intra-Cellular Therapies Inc. was a new CIBRA Capital position in Q1 2025.
  • Intra-Cellular Therapies Inc. made up 18.76% of CIBRA Capital's portfolio in Q1 2025, its #1 holding.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on CIBRA Capital's 13F filing for Q1 2025, filed 28 Apr 2025.